Recursion Pharmaceuticals, Inc. used an unbiased, ML-powered genomics screen to rapidly identify and advance REC-1245, a potential first-in-class RNA-binding motif protein 39 (RBM39) degrader targeting solid tumors and lymphoma identification to regulatory approval in under 18 months, more than twice as fast as the industry average. This evidence concerns the gene RBM39 and lymphoma.